Human tumor antigens yesterday, today, and tomorrow

Cancer Immunology Research

Volumn 5, Issue 5, 2017, Pages 347-354

  Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLYCOPEPTIDE; PHOSPHOPEPTIDE; TUMOR ANTIGEN;

ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CELLULAR IMMUNITY; COMPARATIVE STUDY; DRUG POTENCY; GENE FUSION; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IMMUNOLOGIST; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; MULTIPLE MYELOMA; PANCREAS CANCER; PERSONALIZED MEDICINE; PRIMARY PREVENTION; PRIMARY TUMOR; T CELL LYMPHOMA; TROPHOBLAST; TUMOR IMMUNOGENICITY; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; WHOLE EXOME SEQUENCING; ANIMAL; IMMUNOLOGY; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; NEOPLASMS;

EID: 85018449836     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-17-0112     Document Type: Article

References (69)

1. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957;18:769-78.
2. Klein G, Sjogren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960;20:1561-72.
3. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
4. Barnd DL, LanMS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-Associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A 1989;86:7159-63.
5. Lan MS, Finn OJ, Fernsten PD, Metzgar RS. Isolation and properties of a human pancreatic adenocarcinoma-Associated antigen, DU-PAN-2. Cancer Res 1985;45:305-10.
6. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989;43:1072-6.
7. Hull SR, Bright A, Carraway KL, Abe M, Hayes DF, Kufe DW. Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun 1989;1:261-7.
8. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, et al. Molecular cloning and expression of human tumor-Associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-93.
9. Gendler SJ, Burchell JM, Duhig T, Lamport D, White R, Parker M, et al. Cloning of partial cDNA encoding differentiation and tumor-Associated mucin glycoproteins expressed by humanmammary epithelium. Proc Natl Acad Sci U S A 1987;84:6060-4.
10. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinomaassociated antigen. Proc Natl Acad Sci U S A 1988;85:2320-3.
11. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991;51:2908-16.
12. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBVimmortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993;151:1654-62.
13. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995;155:4766-74.
14. Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-Tandem repeats of human mucin (muc-1) protein core. Cancer Res 1993;53:5386-94.
15. Fontenot JD, Finn OJ, Dales N, Andrews PC, Montelaro RC. Synthesis of large multideterminant peptide immunogens using a poly-proline betaturn helix motif. Pept Res 1993;6:330-6.
16. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
17. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, et al. Characterization of peptides bound to the class IMHCmolecule HLAA2.1 by mass spectrometry. Science 1992;255:1261-3.
18. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
19. Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, et al. Identification of cyclin B1 as a shared human epithelial tumorassociated antigen recognized by T cells. J Exp Med 2001;194:1313-23.
20. Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005;11:1521-6.
21. Egloff AM, Vella LA, FinnOJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006;66:6-9.
22. del Guercio MF, Alexander J, Kubo RT, Arrhenius T, Maewal A, Appella E, et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997;15:441-8.
23. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999;284:1351-4.
24. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54:721-8.
25. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: Molecular definition and implications. Mol Med Today 1997;3:342-9.
26. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;9:709-16.
27. Soliman C, Yuriev E, Ramsland PA. Antibody recognition of aberrant glycosylation on the surface of cancer cells. Curr Opin Struct Biol 2016;44:1-8.
28. Satomaa T, Heiskanen A, Leonardsson I, Angström J, Olonen A, Blomqvist M, et al. Analysis of the human cancer glycome identifies a novel group of tumor-Associated N-Acetylglucosamine glycan antigens. Cancer Res 2009; 69:5811-9.
29. Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-27.
30. Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, et al. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol 2014;92:153-65.
31. Sadelain M. Chimeric antigen receptors: Driving immunology towards synthetic biology. Curr Opin Immunol 2016;41:68-76.
32. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005;54:187-207.
33. Ryan SO, Vlad AM, Islam K, Gariepy J, Finn OJ. Tumor-Associated MUC1 glycopeptide epitopes are not subject to self-Tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenicmice. Biol Chem 2009;390:611-8.
34. Cobbold M, De La Pena H, Norris A, Polefrone JM, Qian J, English AM, et al. MHC class I-Associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 2013;5:203ra125.
35. Depontieu FR, Qian J, Zarling AL, McMiller TL, Salay TM, Norris A, et al. Identification of tumor-Associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A 2009; 106:12073-8.
36. Brentville VA, Metheringham RL, Gunn B, Symonds P, Daniels I, Gijon M, et al. Citrullinated vimentin presented on MHC-II in tumor cells is a target for CD4+ T-cell-mediated antitumor immunity. Cancer Res 2016;76:548-60.
37. Finn OJ. Cancer vaccines: Between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
38. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
39. Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492-9.
40. Hanahan D, Coussens LM. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-22.
41. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74-80.
42. Romero P, Banchereau J, BhardwajN, Cockett M, DisisML, Dranoff G, et al. The Human Vaccines Project: A roadmap for cancer vaccine development. Sci Transl Med 2016;8:334ps9.
43. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015;27: 450-61.
44. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
45. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
46. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 2016;16:219-33.
47. Finn OJ, Beatty PL. Cancer immunoprevention. Curr Opin Immunol 2016;39:52-8.
48. Finn OJ, Forni G. Prophylactic cancer vaccines. Curr Opin Immunol 2002;14:172-7.
49. Chu NJ, Armstrong TD, Jaffee EM. Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res 2015;21:1549-57.
50. Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008;6:955-64.
51. Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254-64.
52. Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, et al. Tn-MUC1 DC vaccination of rhesus macaques and a phase I/II trial in patients with nonmetastatic castrate-resistant prostate cancer. Cancer Immunol Res 2016;4:881-92.
53. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al.MUC1vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 2013;6:18-26.
54. Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, et al. Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep 2016;6: 31740.
55. Cramer DW, Finn OJ. Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 2011;23:265-71.
56. Cramer DW, Vitonis AF, Pinheiro SP, McKolanis JR, Fichorova RN, Brown KE, et al. Mumps and ovarian cancer: Modern interpretation of an historic association. Cancer Causes Control 2010;21:1193-201.
57. Pinheiro SP, Hankinson SE, Tworoger SS, Rosner BA, McKolanis JR, Finn OJ, et al. Anti-MUC1 antibodies and ovarian cancer risk: Prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 2010;19:1595-601.
58. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:30-5.
59. Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, et al. Conditions associated with antibodies against the tumorassociated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125-31.
60. Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci U S A 2009;106:14010-5.
61. Pandey JP, Kistner-Griffin E, Namboodiri AM, Iwasaki M, Kasuga Y, Hamada GS, et al. Higher levels of antibodies to the tumour-Associated antigen cyclin B1 in cancer-free individuals than in patients with breast cancer. Clin Exp Immunol 2014;178:75-8.
62. Leisenfelder SA, Moffat JF. Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclindependent kinase activity. J Virol 2006;80:5577-87.
63. Sanchez V, Spector DH. Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles. J Virol 2006;80:5886-96.
64. Amirian ES, Scheurer ME, Zhou R, Wrensch MR, Armstrong GN, Lachance D, et al. History of chickenpox in glioma risk: A report from the glioma international case-control study (GICC). Cancer Med 2016;5:1352-8.
65. Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 2015;126: 2475-8.
66. Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, et al. Expression of cancer testis antigens in human BRCA-Associated breast cancers: Potential targets for immunoprevention? Cancer Immunol Immunother 2011;60:999-1007.
67. Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget 2016;7: 66192-201.
68. Hale DF, Vreeland TJ, Peoples GE. Arming the immune system through vaccination to prevent cancer recurrence. Am Soc Clin Oncol Educ Book 2016;35:e159-67.
69. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-37.